Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2017-01-23 Regulatory Filings
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1 for AnaptysBio, Inc. It discusses the distribution of a Preliminary Prospectus and requests acceleration of the effectiveness of the Registration Statement. This is a communication related to the registration and offering process of securities, specifically an underwriters' acceleration request. It is not a financial report, earnings release, or any other type of report but rather a regulatory filing related to securities registration. The document length is short and it is a formal correspondence with the SEC, fitting the category of Regulatory Filings (RNS).
2017-01-23 English
Regulatory Filings 2017
Regulatory Filings Classification · 100% confidence The document is a letter from AnaptysBio, Inc. to the SEC requesting acceleration of effectiveness for a Form S-1 Registration Statement under Rule 461 of the Securities Act of 1933. It is a correspondence related to a registration statement filing, not a financial report or earnings release. The document is short (1807 characters) and is a formal request related to a regulatory filing process. It does not contain financial data, management discussion, or report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence with the SEC that do not fit other categories.
2017-01-23 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It is a registration statement for securities listing on NASDAQ. The document is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration. The document length is short (3094 characters) and it is a formal SEC form. Therefore, it fits best under Regulatory Filings (RNS) as it does not match any other specific report or announcement category.
2017-01-17 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to the initial public offering (IPO) of AnaptysBio, Inc. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, management discussion, and other disclosures typical of a registration statement for securities offering. This type of filing is not an annual report, earnings release, or any other financial report but a capital markets filing related to the company's financing and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-01-17 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding AnaptysBio, Inc.'s Registration Statement on Form S-1 for its proposed IPO. It discusses valuation considerations related to the company's equity awards and the anticipated price range for the IPO. The letter references prior response letters and valuation reports used to determine the fair value of the company's common stock. It is a supplemental communication to assist the SEC staff in their review of the Registration Statement. The document is not the Registration Statement itself, nor is it a financial report or earnings release. It is a regulatory correspondence related to the IPO registration process, specifically addressing valuation and pricing issues. Therefore, it fits best under Regulatory Filings (RNS), as it is a regulatory submission that does not fit into other specific categories like Annual Report, Earnings Release, or Capital Update.
2017-01-11 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from the company's legal counsel to the SEC Division of Corporation Finance. It addresses comments on a previously filed Registration Statement on Form S-1, specifically amendments and clarifications related to clinical trial disclosures. The document references the Registration Statement and amendments but does not contain financial statements or substantive financial data itself. It is a regulatory correspondence responding to SEC comments, not a report or announcement of financial results or corporate actions. The document length is short (2992 characters) and is clearly a letter responding to regulatory comments, fitting the category of Regulatory Filings (RNS) as a fallback for such correspondence.
2016-12-28 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.